Anti-dll3 antibody

Patent metadata

Field	Value
Publication number	US-2016244530-A2
Application number	US-201514846135-A
Country	US
Kind code	A2
Filing date	Sep 4, 2015
Priority date	Jan 29, 2010
Publication date	Aug 25, 2016
Grant date	—

Abstract

It is intended to disclose an antibody which binds to DLL3 protein. Preferably, the antibody of the present invention recognizes a region from amino acids 216 to 492 in human DLL3 having the amino acid sequence as set forth in SEQ ID NO: 1. The present invention also provides a pharmaceutical composition, for example, an anticancer agent, comprising the antibody of the present invention as an active ingredient. The present invention further discloses a method for diagnosing cancer using the antibody of the present invention and a diagnostic drug for cancer comprising the antibody of the present invention.

First claim

1 . An anti-DLL3 antibody which can bind to DLL3 having the amino acid sequence set forth in SEQ ID NO: 1, wherein the antibody has an internalizing activity and conjugates one or more cytotoxic substances.

2 . The anti-DLL3 antibody according to claim 1 , wherein the antibody can bind to an epitope located between residues 27 and 175 of SEQ ID NO: 1.

3 . The anti-DLL3 antibody according to claim 1 , wherein the antibody can bind to an epitope located between residues 27 and 215 of SEQ ID NO: 1.

4 . The anti-DLL3 antibody according to claim 1 , wherein the antibody is a chimera or humanized antibody.

5 . A method of inducing death of a cell expressing DLL3 having the amino acid sequence set forth in SEQ ID NO: 1 comprising contacting the cell with an anti-DLL3 antibody conjugated to one or more cytotoxic substances, wherein the antibody has an internalizing activity.

6 . The method according to claim 5 , wherein the antibody can bind to an epitope located between residues 27 and 175 of SEQ ID NO: 1.

7 . The method according to claim 5 , wherein the antibody can bind to an epitope located between residues 27 and 215 of SEQ ID NO: 1.

8 . The method according to claim 5 , wherein the antibody is a chimera or humanized antibody.

9 . A method of suppressing growth of a cell expressing DLL3 as set forth in SEQ ID NO: 1 comprising contacting the cell with an anti-DLL3 antibody conjugated to one or more cytotoxic substances.

10 . The method according to claim 9 , wherein the antibody can bind to an epitope located between residues 27 and 175 of SEQ ID NO: 1.

11 . The method according to claim 9 , wherein the antibody can bind to an epitope located between residues 27 and 215 of SEQ ID NO: 1.

12 . The method according to claim 9 , wherein the antibody is a chimera or humanized antibody.

13 . A method of treating cancer comprising administering an anti-DLL3 antibody which can bind to DLL3 having the amino acid sequence set forth in SEQ ID NO: 1 to a subject having cancer or suspected of having cancer, wherein the antibody has an internalizing activity and is conjugated to one or more cytotoxic substances.

14 . The method according to claim 13 , wherein the antibody can bind to an epitope located between residues 27 and 175 of SEQ ID NO: 1.

15 . The method according to claim 13 , wherein the antibody can bind to an epitope located between residues 27 and 215 of SEQ ID NO: 1.

16 . The method according to claim 13 , wherein the antibody is a chimera or humanized antibody.

17 . The method according to claim 13 , wherein the cancer is a lung cancer.

18 . The method according to claim 17 , wherein the lung cancer is a small-cell lung cancer.

Assignees

• Chugai Pharmaceutical Co Ltd
• Univ Tokyo

Inventors

• Yoshida Kenji
• Aburatani Hiroyuki
• Ishikawa Shumpei

Classifications

• G01N33/575

  for cancer · CPC title

• C07K2317/30

  characterized by aspects of specificity or valency · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K16/3023 Primary

  Lung · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title